{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T17:21:19Z","timestamp":1781716879261,"version":"3.54.5"},"reference-count":38,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1016\/j.antiviral.2010.03.004","type":"journal-article","created":{"date-parts":[[2010,3,15]],"date-time":"2010-03-15T09:35:20Z","timestamp":1268645720000},"page":"261-267","source":"Crossref","is-referenced-by-count":47,"title":["Efficacy of 2\u2032-C-methylcytidine against yellow fever virus in cell culture and in a hamster model"],"prefix":"10.1016","volume":"86","author":[{"given":"Justin G.","family":"Julander","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashok K.","family":"Jha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Ae","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kie-Hoon","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald F.","family":"Smee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Morrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung K.","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2010.03.004_bib1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1177\/095632020801900104","article-title":"Combinations of 2\u2032-C-methylcytidine analogues with interferon-alpha2b and triple combination with ribavirin in the hepatitis C virus replicon system","volume":"19","author":"Bassit","year":"2008","journal-title":"Antivir. Chem. Chemother."},{"key":"10.1016\/j.antiviral.2010.03.004_bib2","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.antiviral.2006.08.005","article-title":"Antiviral activity of CHO-SS cell-derived human omega interferon and other human interferons against HCV RNA replicons and related viruses","volume":"73","author":"Buckwold","year":"2007","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2010.03.004_bib3","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2174\/187152606776056698","article-title":"Nucleoside analog inhibitors of hepatitis C virus replication","volume":"6","author":"Carroll","year":"2006","journal-title":"Infect. Disord. Drug Targets"},{"key":"10.1016\/j.antiviral.2010.03.004_bib4","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.antiviral.2004.06.007","article-title":"Rodent models for the study of therapy against flavivirus infections","volume":"63","author":"Charlier","year":"2004","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2010.03.004_bib5","doi-asserted-by":"crossref","first-page":"5504","DOI":"10.1021\/jm0502788","article-title":"Design, synthesis, and antiviral activity of 2\u2032-deoxy-2\u2032-fluoro-2\u2032-C-methylcytidine, a potent inhibitor of hepatitis C virus replication","volume":"48","author":"Clark","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2010.03.004_bib6","doi-asserted-by":"crossref","first-page":"3444","DOI":"10.1128\/AAC.00372-06","article-title":"Ribavirin antagonizes the in vitro anti-hepatitis C virus activity of 2\u2032-C-methylcytidine, the active component of valopicitabine","volume":"50","author":"Coelmont","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2010.03.004_bib7","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1517\/14740330902808086","article-title":"Safety of 17D derived yellow fever vaccines","volume":"8","author":"Domingo","year":"2009","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.antiviral.2010.03.004_bib8","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1093\/nass\/nrn306","article-title":"Synthesis and antiviral activity of novel derivatives of 2\u2032-beta-C-methylcytidine","author":"Fogt","year":"2008","journal-title":"Nucl. Acids Symp. Ser. (Oxf.)"},{"key":"10.1016\/j.antiviral.2010.03.004_bib9","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.antiviral.2006.09.007","article-title":"2\u2032-C-methylcytidine as a potent and selective inhibitor of the replication of foot-and-mouth disease virus","volume":"73","author":"Goris","year":"2007","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2010.03.004_bib10","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.trstmh.2007.06.013","article-title":"Acute viscerotropic disease following vaccination against yellow fever","volume":"101","author":"Hayes","year":"2007","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"10.1016\/j.antiviral.2010.03.004_bib11","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1128\/AAC.01494-06","article-title":"Activity of T-1106 in a hamster model of yellow fever virus infection","volume":"51","author":"Julander","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2010.03.004_bib12","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.antiviral.2006.08.008","article-title":"Comparison of the inhibitory effects of interferon alfacon-1 and ribavirin on yellow fever virus infection in a hamster model","volume":"73","author":"Julander","year":"2007","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2010.03.004_bib13","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1128\/AAC.01074-08","article-title":"Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106","volume":"53","author":"Julander","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2010.03.004_bib14","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/0470058005.ch8","article-title":"Finding new medicines for flaviviral targets","volume":"277","author":"Keller","year":"2006","journal-title":"Novartis Found. Symp."},{"key":"10.1016\/j.antiviral.2010.03.004_bib15","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/S0168-8278(07)61612-2","article-title":"Clearance of HCV RNA with valopicitabine (NM) plus peg-interferon in treatment-naive patients with HCV-1 infection: results at 24 and 48 weeks","volume":"46","author":"Lawitz","year":"2007","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2010.03.004_bib16","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1089\/apc.2007.0199","article-title":"Hepatitis C protease and polymerase inhibitors in development","volume":"22","author":"Liu-Young","year":"2008","journal-title":"AIDS Patient Care STDS"},{"key":"10.1016\/j.antiviral.2010.03.004_bib17","doi-asserted-by":"crossref","first-page":"e1000614","DOI":"10.1371\/journal.ppat.1000614","article-title":"A mouse model for studying viscerotropic disease caused by yellow fever virus infection","volume":"5","author":"Meier","year":"2009","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2010.03.004_bib18","first-page":"341","article-title":"Yellow fever as an endemic\/epidemic disease and priorities for vaccination","volume":"99","author":"Monath","year":"2006","journal-title":"Bull. Soc. Pathol. Exot."},{"key":"10.1016\/j.antiviral.2010.03.004_bib19","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.antiviral.2007.10.009","article-title":"Treatment of yellow fever","volume":"78","author":"Monath","year":"2008","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2010.03.004_bib20","doi-asserted-by":"crossref","first-page":"431","DOI":"10.4269\/ajtmh.1981.30.431","article-title":"Pathophysiologic correlations in a rhesus monkey model of yellow fever with special observations on the acute necrosis of B cell areas of lymphoid tissues","volume":"30","author":"Monath","year":"1981","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.antiviral.2010.03.004_bib21","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1128\/AAC.00400-06","article-title":"Mechanism of activation of beta-d-2\u2032-deoxy-2\u2032-fluoro-2\u2032-c-methylcytidine and inhibition of hepatitis C virus NS5B RNA polymerase","volume":"51","author":"Murakami","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2010.03.004_bib22","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1128\/AAC.01184-07","article-title":"The mechanism of action of beta-d-2\u2032-deoxy-2\u2032-fluoro-2\u2032-C-methylcytidine involves a second metabolic pathway leading to beta-d-2\u2032-deoxy-2\u2032-fluoro-2\u2032-C-methyluridine 5\u2032-triphosphate, a potent inhibitor of the hepatitis C virus RNA-dependent RNA polymerase","volume":"52","author":"Murakami","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2010.03.004_bib23","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.antiviral.2006.06.006","article-title":"Selective inhibitors of hepatitis C virus replication","volume":"71","author":"Neyts","year":"2006","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2010.03.004_bib24","doi-asserted-by":"crossref","first-page":"6614","DOI":"10.1021\/jm0603623","article-title":"Synthesis and pharmacokinetics of valopicitabine (NM283), an efficient prodrug of the potent anti-HCV agent 2\u2032-C-methylcytidine","volume":"49","author":"Pierra","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2010.03.004_bib25","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1081\/NCN-200060112","article-title":"Nm 283, an efficient prodrug of the potent anti-HCV agent 2\u2032-C-methylcytidine","volume":"24","author":"Pierra","year":"2005","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.1016\/j.antiviral.2010.03.004_bib26","first-page":"493","article-title":"A simple method of estimating fifty percent endpoint","volume":"27","author":"Reed","year":"1938","journal-title":"Am. J. Hyg."},{"key":"10.1016\/j.antiviral.2010.03.004_bib27","doi-asserted-by":"crossref","first-page":"306","DOI":"10.4269\/ajtmh.2004.71.306","article-title":"Efficacy of post-exposure treatment of yellow fever with ribavirin in a hamster model of the disease","volume":"71","author":"Sbrana","year":"2004","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.antiviral.2010.03.004_bib28","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.4269\/ajtmh.2006.74.1084","article-title":"Experimental yellow fever virus infection in the golden hamster (Mesocricetus auratus) III. Clinical laboratory values","volume":"74","author":"Sbrana","year":"2006","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.antiviral.2010.03.004_bib29","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1128\/AAC.20.6.769","article-title":"Evaluation of carbodine, the carbocyclic analog of cytidine, and related carbocyclic analogs of pyrimidine nucleosides for antiviral activity against human influenza Type A viruses","volume":"20","author":"Shannon","year":"1981","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2010.03.004_bib30","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1128\/AAC.01051-06","article-title":"Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice","volume":"51","author":"Sidwell","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2010.03.004_bib31","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1128\/AEM.22.5.797-801.1971","article-title":"Use of disposable micro tissue culture plates for antiviral and interferon induction studies","volume":"22","author":"Sidwell","year":"1971","journal-title":"Appl. Microbiol."},{"key":"10.1016\/j.antiviral.2010.03.004_bib32","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1177\/095632020601700203","article-title":"Inhibition of hepatitis C replicon RNA synthesis by beta-d-2\u2032-deoxy-2\u2032-fluoro-2\u2032-C-methylcytidine: a specific inhibitor of hepatitis C virus replication","volume":"17","author":"Stuyver","year":"2006","journal-title":"Antivir. Chem. Chemother."},{"key":"10.1016\/j.antiviral.2010.03.004_bib33","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1086\/320199","article-title":"Experimental yellow fever virus infection in the Golden Hamster (Mesocricetus auratus). I. Virologic, biochemical, and immunologic studies","volume":"183","author":"Tesh","year":"2001","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2010.03.004_bib34","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1080\/10408360490497474","article-title":"Yellow fever: the recurring plague","volume":"41","author":"Tomori","year":"2004","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"10.1016\/j.antiviral.2010.03.004_bib35","first-page":"150","article-title":"Valopicitabine dihydrochloride: a specific polymerase inhibitor of hepatitis C virus","volume":"8","author":"Toniutto","year":"2007","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.antiviral.2010.03.004_bib36","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.trstmh.2006.04.001","article-title":"Clinical and epidemiological characteristics of yellow fever in Brazil: analysis of reported cases 1998\u20132002","volume":"101","author":"Tuboi","year":"2007","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"10.1016\/j.antiviral.2010.03.004_bib37","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1086\/320200","article-title":"Experimental yellow fever virus infection in the Golden hamster (Mesocricetus auratus). II. Pathology","volume":"183","author":"Xiao","year":"2001","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2010.03.004_bib38","doi-asserted-by":"crossref","first-page":"20435","DOI":"10.1073\/pnas.0907010106","article-title":"An adenosine nucleoside inhibitor of dengue virus","volume":"106","author":"Yin","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U.S.A."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016635421000389X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016635421000389X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T01:05:50Z","timestamp":1591146350000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016635421000389X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["S016635421000389X"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2010.03.004","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2010,6]]}}}